Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Search

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Year: 2008

Clear Catheter Systems Growing

September 1, 2008June 22, 2015 by James Herlofsky

Today’s Medical Developments

Filter Posts

Filter Posts

Recent Posts

With Retained Blood, Bleeding Begets More Bleeding after Cardiac Surgery
Level 1A Evidence that Reducing Retained Blood Prevents POAF and Effusions After Cardiac Surgery
Preparing for the Shift to Cardiac Surgery Value Based Bundled Care Payments
Expert Consensus Opinion Suggest Preventing Retained Blood To Reduce Infections After Cardiac Surgery
ICU Bottlenecks after Cardiac Surgery: The case for active clearance of chest tubes

Archives

2017
2016
2015
2014
2013
2012
2011
2010
2009
2008

ChallengeRetained Blood Syndrome
SolutionPleuraFlow® ACT
MissionA New Standard

Blog
About
Press
FAQ
Resources
Education
Sales
Cost Calculator
Contact

Clinical References| Terms of Use| PleuraFlow ACT System Indications of Use|

ClearFlow’s PleuraFlow® Active Clearance Technology® and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759, 8,702,662 and 8,951,355. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow’s patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.

Website by Bloom Creative